The Betami and Danblock trials investigated the effect of beta-blockers vs. no beta-blockers on the primary endpoint of all-cause mortality and major adverse cardiovascular events in patients after an MI with LVEF ≥40 %. A significant reduction in the primary endpoint was observed with beta-blockers compared with no beta-blockers. These results suggest that, despite advances in contemporary MI treatment, the beneficial effects of beta-blockers remain clinically relevant, even in patients with preserved or mildly reduced LVEF.
Read on